Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't
PubMed
32948844
PubMed Central
PMC8179850
DOI
10.1038/s41375-020-01022-2
PII: 10.1038/s41375-020-01022-2
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Blood Transfusion mortality MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Myelodysplastic Syndromes mortality pathology therapy MeSH
- Follow-Up Studies MeSH
- Iron Overload etiology metabolism mortality pathology MeSH
- Prognosis MeSH
- Prospective Studies MeSH
- Aged MeSH
- Iron adverse effects MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Iron MeSH
Center of Hematology and Bone Marrow Transplantation Fundeni Clinical Institute Bucharest Romania
Centre for Clinical Transfusion Research Sanquin Research Leiden The Netherlands
Department of Clinical Epidemiology Leiden University Medical Center Leiden The Netherlands
Department of Clinical Hematology Institute of Hematology and Blood Transfusion Praha Czech Republic
Department of Haematology Warrington and Halton Teaching Hospitals NHS foundation Trust Cheshire UK
Department of Hematology Aberdeen Royal Infirmary Aberdeen UK
Department of Hematology Airedale NHS Trust Airdale UK
Department of Hematology Blackpool Victoria Hospital Blackpool Lancashire UK
Department of Hematology Coltea Clinical Hospital Bucharest Romania
Department of Hematology Radboud University Medical Center Nijmegen The Netherlands
Department of Hematology Royal Bournemouth Hospital Bournemouth UK
Department of Medicine Division of Hematology Karolinska Institutet Stockholm Sweden
Department of Medicine Division of Hematology University of Patras Medical School Patras Greece
Epidemiology and Cancer Statistics Group University of York York UK
St James's Institute of Oncology Leeds Teaching Hospitals Leeds UK
See more in PubMed
Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2008;1:166–75. doi: 10.1182/asheducation-2008.1.166. PubMed DOI
Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–603. doi: 10.1200/JCO.2005.01.7038. PubMed DOI
Leitch HA, Fibach E, Rachmilewitz E. Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies. Crit Rev Oncol Hematol. 2017;113:156–70. doi: 10.1016/j.critrevonc.2017.03.002. PubMed DOI
Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124:873–81. doi: 10.1182/blood-2014-03-563221. PubMed DOI PMC
de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, et al. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2018;103:69–79. doi: 10.3324/haematol.2017.171884. PubMed DOI PMC
Porter JB, de Witte T, Cappellini MD, Gattermann N. New insights into transfusion-related iron toxicity: Implications for the oncologist. Crit Rev Oncol Hematol. 2016;99:261–71. doi: 10.1016/j.critrevonc.2015.11.017. PubMed DOI
Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823:1434–43. doi: 10.1016/j.bbamcr.2012.01.014. PubMed DOI PMC
Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678–84. doi: 10.1038/ng.2996. PubMed DOI PMC
Ye ZW, Zhang J, Townsend DM, Tew KD. Oxidative stress, redox regulation and diseases of cellular differentiation. Biochim Biophys Acta. 2015;1850:1607–21. doi: 10.1016/j.bbagen.2014.11.010. PubMed DOI PMC
Pimková K, Chrastinová L, Suttnar J, Štikarová J, Kotlín R, Čermák J, et al. Plasma levels of aminothiols, nitrite, nitrate, and malondialdehyde in myelodysplastic syndromes in the context of clinical outcomes and as a consequence of iron overload. Oxid Med Cell Longev. 2014;2014:416028. doi: 10.1155/2014/416028. PubMed DOI PMC
Pilo F, Angelucci E. A storm in the niche: Iron, oxidative stress and haemopoiesis. Blood Rev. 2018;32:29–35. doi: 10.1016/j.blre.2017.08.005. PubMed DOI
de Souza GF, Barbosa MC, Santos TE, Carvalho TM, de Freitas RM, Martins MR, et al. Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes. J Clin Pathol. 2013;66:996–8. doi: 10.1136/jclinpath-2012-201288. PubMed DOI
Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS ONE. 2011;6:e23109. doi: 10.1371/journal.pone.0023109. PubMed DOI PMC
Ambaglio I, Malcovati L, Papaemmanuil E, Laarakkers CM, Della Porta MG, Gallì A, et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica. 2013;98:420–3. doi: 10.3324/haematol.2012.077446. PubMed DOI PMC
Zipperer E, Post JG, Herkert M, Kündgen A, Fox F, Haas R, et al. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome. Ann Hematol. 2013;92:1617–23. doi: 10.1007/s00277-013-1839-5. PubMed DOI
